Abdus Salam Abul, FahamBennett, DavidAltin, Joseph2015-12-100264-410Xhttp://hdl.handle.net/1885/52076High-mobility group box 1 (HMGB1) protein is a nuclear binding protein which is released by monocytes and macrophages and is a potent maturation signal for dendritic cells (DCs). Synthetic HMGB1-related peptides are reported to be potent DC stimulants. Two HMGB1-related peptides, denoted as pHMGB-89 and pHMGB-106, were explored for their ability to enhance the immunogenicity of Ag-containing liposomes. pHMGB-engrafted liposomes targeted murine CD11c+ and CD11b+ cells in vitro and in vivo. Vaccination of mice with OVA-containing liposomes engrafted with pHMGB-89 and pHMGB-106 induced OVA-specific T cell priming and production of IgG1, IgG2a and IgG2b antibodies. Importantly, vaccination of mice with B16-OVA-derived plasma membrane vesicles (PMVs) engrafted with pHMGB-89 and pHMGB-106 inhibited tumour growth and metastasis, in syngeneic mice challenged with highly metastatic B16-OVA melanoma. The results show that vaccination with Ag-containing liposomes/PMVs engrafted with HMGB1 peptides could be an effective approach for developing novel vaccines and cancer immunotherapies.Keywords: high mobility group B1 protein; immunoglobulin G1; immunoglobulin G2a; immunoglobulin G2b; liposome; peptide derivative; animal cell; animal experiment; animal model; article; cancer immunization; controlled study; drug formulation; female; immunoglobulin Chelator lipid; HMGB1 peptides; Plasma membrane vesicles; Stealth liposomes; Tumour immunotherapy; Vaccines200910.1016/j.vaccine.2009.07.0532016-02-24